SWEDEPAD Reassesses Paclitaxel Safety Amidst Device Failure in Peripheral Artery Disease
The SWEDEPAD trials found that paclitaxel-coated devices do not improve outcomes like amputation risk or quality of life in peripheral arterial disease and may be associated with increased five-year mortality, reigniting safety concerns about these devices.